Baxter International 관리

관리 기준 확인 3/4

Baxter International CEO는 Joe Almeida, Jan2016 에 임명되었습니다 의 임기는 8.92 년입니다. 총 연간 보상은 $ 13.79M, 9.4% 로 구성됩니다. 9.4% 급여 및 90.6% 보너스(회사 주식 및 옵션 포함). 는 € 15.75M 가치에 해당하는 회사 주식의 0.11% 직접 소유합니다. 15.75M. 경영진과 이사회의 평균 재임 기간은 각각 2.2 년과 4.8 년입니다.

주요 정보

Joe Almeida

최고 경영자

US$13.8m

총 보상

CEO 급여 비율	9.4%
CEO 임기	8.9yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	2.2yrs
이사회 평균 재임 기간	4.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Joe Almeida 의 보수는 Baxter International 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	US$121m
Jun 30 2024	n/a	n/a	US$98m
Mar 31 2024	n/a	n/a	-US$38m
Dec 31 2023	US$14m	US$1m	-US$76m
Sep 30 2023	n/a	n/a	US$96m
Jun 30 2023	n/a	n/a	-US$3b
Mar 31 2023	n/a	n/a	-US$3b
Dec 31 2022	US$14m	US$1m	-US$3b
Sep 30 2022	n/a	n/a	-US$3b
Jun 30 2022	n/a	n/a	US$876m
Mar 31 2022	n/a	n/a	US$992m
Dec 31 2021	US$16m	US$1m	US$1b
Sep 30 2021	n/a	n/a	US$1b
Jun 30 2021	n/a	n/a	US$1b
Mar 31 2021	n/a	n/a	US$1b
Dec 31 2020	US$16m	US$1m	US$1b
Sep 30 2020	n/a	n/a	US$911m
Jun 30 2020	n/a	n/a	US$924m
Mar 31 2020	n/a	n/a	US$991m
Dec 31 2019	US$14m	US$1m	US$1b
Sep 30 2019	n/a	n/a	US$1b
Jun 30 2019	n/a	n/a	US$1b
Mar 31 2019	n/a	n/a	US$2b
Dec 31 2018	US$16m	US$1m	US$2b
Sep 30 2018	n/a	n/a	US$1b
Jun 30 2018	n/a	n/a	US$795m
Mar 31 2018	n/a	n/a	US$840m
Dec 31 2017	US$15m	US$1m	US$609m

보상 대 시장: Joe 의 총 보상 ($USD 13.79M )은 German 시장( $USD 4.86M ).

보상과 수익: Joe 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Joe Almeida (62 yo)

8.9yrs

테뉴어

US$13,786,671

보상

Mr. Jose E. Almeida, also known as Joe, has been the Chairman of the Board and Chief Executive Officer of Baxter International Inc. since January 1, 2016 and serves as its President since January 01, 2016....

리더십 팀

이름	위치	테뉴어	보상	소유권
Jose Almeida	Chairman of the Board	8.9yrs	US$13.79m	0.11% € 15.7m
Joel Grade	Executive VP	1.2yrs	US$5.37m	0.0028% € 391.7k
Heather Knight	Executive VP & Group President of Medical Products and Therapies	1.8yrs	US$4.86m	0.031% € 4.4m
Alok Sonig	Executive VP & Group President of Pharmaceuticals	2.4yrs	US$3.87m	0.0024% € 333.8k
Christopher Toth	Executive VP & Group President of Kidney Care	1.5yrs	US$9.64m	0.0046% € 644.9k
Tobi Karchmer	Senior VP and Chief Medical & Scientific Officer	1.9yrs	데이터 없음	데이터 없음
Charles Patel	Senior VP & Chief Information Officer	less than a year	데이터 없음	데이터 없음
Clare Trachtman	Vice President of Investor Relations	no data	데이터 없음	데이터 없음
David Rosenbloom	Executive VP & General Counsel	2.7yrs	US$5.66m	0.0018% € 256.0k
Stacey Eisen	Senior Vice President	no data	데이터 없음	데이터 없음
Jeanne Mason	Executive VP & Chief Human Resources Officer	7.6yrs	US$4.14m	0.037% € 5.2m
James Borzi	Executive VP & Chief Supply Chain Officer	4.9yrs	데이터 없음	0.0036% € 507.7k

2.2yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: BTL 의 관리팀은 경험 ( 2.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jose Almeida	Chairman of the Board	8.9yrs	US$13.79m	0.11% € 15.7m
Stephen Rusckowski	Independent Director	1.3yrs	US$197.82k	0.0018% € 251.7k
Robert Parkinson	Chairman Emeritus	8.9yrs	US$17.88m	데이터 없음
Peter Wilver	Independent Director	2.6yrs	US$349.64k	0.0026% € 367.7k
Stephen Newman Oesterle	Independent Director	7.8yrs	US$373.98k	0.0055% € 772.2k
Patricia Morrison	Independent Director	5.8yrs	US$364.98k	0.0042% € 591.1k
Nancy Schlichting	Independent Director	3yrs	US$363.00k	0.0028% € 396.0k
Catherine Smith	Independent Director	7.9yrs	US$367.31k	0.0044% € 625.1k
David Shafer	Lead Independent Director	2.6yrs	US$382.31k	0.0026% € 367.7k
David Wilkes	Independent Director	3.8yrs	US$357.00k	0.0032% € 451.1k
William Ampofo	Independent Director	1.5yrs	US$226.35k	0.0019% € 272.9k
Amy Wendell	Independent Director	5.8yrs	US$352.98k	데이터 없음

4.8yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: BTL 의 이사회는 경험(평균 재직 기간 4.8 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/20 12:53
장 마감 주가	2024/12/20 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Baxter International Inc. 46 애널리스트 중 13 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Jasper Hellweg	Argus Research Company
Benjamin Yeoh	Atlantic Equities LLP
Daniel Owczarski	Avondale Partners

Baxter International 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Baxter International Inc. Announces Resignation of Peter M. Wilver as Board of Directors, and the Audit Committee and Compensation and Human Capital Committee, Effective December 31, 2024

-Baxter International Inc. Appoints Jeffrey A. Craig to Its Board

Baxter International Inc., Annual General Meeting, May 07, 2024

Baxter International Inc. Announces Management Appointments

Baxter International Inc. Announces Board Changes

High number of new directors

Recent updates

Baxter International Inc. Announces Continued Growth of Pharmaceuticals Portfolio with Five Injectable Product Launches in the U.S

Baxter International Inc. Announces Resignation of Peter M. Wilver as Board of Directors, and the Audit Committee and Compensation and Human Capital Committee, Effective December 31, 2024

Baxter International Inc. Declares Quarterly Dividend, Payable on January 2, 2025

Baxter International Inc. Declares Quarterly Dividend, Payable on January 2, 2025

Baxter International Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2024

Baxter International Inc. Provides Update on North Cove, N.C., Facility

-Baxter International Inc. Appoints Jeffrey A. Craig to Its Board

Upcoming dividend of US$0.29 per share

The Carlyle Group Inc. (NasdaqGS:CG) and Atmas Health entered into an Equity Purchase Agreement to acquire Vantive Health LLC from Baxter International Inc. (NYSE:BAX) for $3.8 billion.

Second quarter 2024 earnings released: US$0.62 loss per share (vs US$0.39 loss in 2Q 2023)

Baxter International Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2024

Baxter International Inc. Announces Launch of the Helion Integrated Surgical System in Thailand

First quarter dividend of US$0.29 announced

Baxter International Inc. Declares Quarterly Dividend, Payable on October 1, 2024

Carlyle Group Reportedly in Advanced Talks to Buy Baxter's Vantive Business

Baxter International Inc. Announces New Data Showing Expanded Hemodialysis, Known as HDX Therapy

Upcoming dividend of US$0.29 per share

Baxter International Inc. Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication

First quarter dividend of US$0.29 announced

Baxter International Inc. Declares Quarterly Dividend, Payable on July 1, 2024

Baxter International Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024

First quarter 2024 earnings released: EPS: US$0.073 (vs US$0.002 loss in 1Q 2023)

Baxter International Inc. Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S

Baxter International Inc. Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy

Baxter International Inc., Annual General Meeting, May 07, 2024

Upcoming dividend of US$0.29 per share

Fourth quarter dividend of US$0.29 announced

Full year 2023 earnings released: US$0.15 loss per share (vs US$4.83 loss in FY 2022)

Baxter International Inc. Provides Sales Guidance for the First Quarter and Full Year 2024

Now 21% overvalued after recent price rise

Baxter International Inc. Announces the Completion of the First Phase of Its Intravenous (IV) Bag Recycling Program Pilot

Upcoming dividend of US$0.29 per share at 3.2% yield

Baxter International Inc. Declares Quarterly Dividend, Payable on January 2, 2024

Baxter International Inc. Highlights New Data At Kidney Week Indicating Sharesource Is Associated with A 77% Lower Risk of Home Dialysis Technique Failure

Baxter International Inc. Provides Earnings Guidance for the Fourth Quarter and Year 2023

Third quarter 2023 earnings released: EPS: US$0.095 (vs US$5.83 loss in 3Q 2022)

Baxter International Inc. Digital Image Capture Capability for PanOptic Plus Ophthalmoscope

Baxter International Inc. Announces Management Appointments

Levi & Korsinsky Notifies Baxter International Inc. Investors of A Class Action Lawsuit and Upcoming Deadline

Upcoming dividend of US$0.29 per share at 2.8% yield

Baxter International Inc. Announces Board Changes

The Klein Law Firm Announces That A Class Action Complaint Has Been Filed on Behalf of Shareholders of Baxter International Inc. Alleging That the Company Violated Federal Securities Laws

Second quarter 2023 earnings released: US$0.39 loss per share (vs US$0.36 profit in 2Q 2022)

Baxter International Inc. Launches PERCLOT Absorbable Hemostatic Powder

Baxter International Inc. Declares Quarterly Cash Dividend, Payable on October 2, 2023

Rosen Law Firm Announces the Filing of Class Action Lawsuit on Behalf of Purchasers of Securities of Baxter International Inc

High number of new directors

Baxter International Inc. Appoints William Ampofo to Its Board of Directors

Baxter International Inc.(NYSE:BAX) dropped from Russell 1000 Growth Index

Upcoming dividend of US$0.29 per share at 2.8% yield

Baxter International Inc. Announces James K. Saccaro Notifies to Resign as Executive Vice President, Effective as of May 31, 2023

Advent International Corporation and Warburg Pincus LLC signed a definitive agreement to acquire Baxter Pharmaceutical Solutions LLC from Baxter International Inc. (NYSE:BAX) for $4.3 billion.

Baxter International Inc. Selects Chris Toth to Be Chief Executive Officer of the Company’s Planned Spinoff of Its Renal Care and Acute Therapies Businesses

First quarter 2023 earnings released: EPS: US$0.087 (vs US$0.14 in 1Q 2022)

Baxter International Inc. Announces Management Changes

Baxter International Inc. Declares Quarterly Dividend, Payable on April 3, 2023

Full year 2022 earnings released: US$4.83 loss per share (vs US$2.56 profit in FY 2021)

Baxter International Inc. Reports Goodwill Impairment for the Fourth Quarter Ended December 31, 2022

Baxter International Inc. Announces Resignation of Giuseppe Accogli as Executive Vice President and Chief Operating Officer

Baxter Introduces ExactaMix Pro Automated Compounder

Upcoming dividend of US$0.29 per share

Baxter International Inc. Declares Quarterly Cash Dividend, Payable on January 3, 2023

Baxter International Inc. Highlights New Home Dialysis and HDX Therapy Data in 14 Clinical Presentations At Kidney Week 2022

Third quarter 2022 earnings released: US$5.83 loss per share (vs US$0.90 profit in 3Q 2021)

Baxter International Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

Baxter International Inc. to Report Q3, 2022 Results on Oct 27, 2022

Baxter International Inc. Announces U.S. FDA Clearance of Novum IQ Syringe Infusion Pump with Dose IQ Safety Software

Upcoming dividend of US$0.29 per share

Second quarter 2022 earnings released: EPS: US$0.25 (vs US$0.59 in 2Q 2021)